Drugs

Acasti Pharma Provides Update On CaPre Phase 3 Development Program

LAVAL, QUEBEC: Outcome of the End-of-Phase 2 Meeting with the FDA Confirms Phase 3 Program is on Track to Start Late 2017 ...

Revive Therapeutics Provides Corporate Update

TORONTO, ONTARIO: ...

Marina Biotech to Present Data on Vascular Resistance and Cancer at the Endocrine Society Annual Meeting on April 1

CITY OF INDUSTRY, CA: ...

VANC Pharmaceuticals Provides Marketing Update

VANCOUVER, BRITISH COLUMBIA: ...

Quadron Closes Cybernetic Control Systems Acquisition

VANCOUVER, BRITISH COLUMBIA: ...

Emblem Corp. Announces Grant of Stock Options

PARIS, ONTARIO: ...

Emblem Corp. Announces Retainer of Nate Nienhuis

PARIS, ONTARIO: ...

Acasti Pharma Forms Scientific Advisory Board and Appoints Two Leading Cardiovascular Disease Experts

LAVAL, QUEBEC: ...

Comprehensive Analysis & Outlook of the Global Epilepsy Market with a Forecast during period 2017-2021

Albany: ...

Acasti Pharma Grants Incentive Stock and Options

LAVAL, QUEBEC: ...